

Zai-Xin Yu

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4097892/zai-xin-yu-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

40 papers	398 citations	11 h-index	19 g-index
44 ext. papers	584 ext. citations	4.2 avg, IF	3.31 L-index

#	Paper	IF	Citations
40	Risk prediction in pulmonary hypertension due to chronic heart failure: incremental prognostic value of pulmonary hemodynamics.. <i>BMC Cardiovascular Disorders</i> , 2022 , 22, 56	2.3	
39	Characteristics, goal-oriented treatments and survival of pulmonary arterial hypertension in China: Insights from a national multicentre prospective registry.. <i>Respirology</i> , 2022 ,	3.6	2
38	LncRNA XIST Facilitates hypoxia-induced myocardial cell injury through targeting miR-191-5p/TRAF3 axis.. <i>Molecular and Cellular Biochemistry</i> , 2022 , 1	4.2	1
37	Association of cardiac injury with hypertension in hospitalized patients with COVID-19 in China. <i>Scientific Reports</i> , 2021 , 11, 22389	4.9	0
36	Association of Systemic Immune-Inflammation Index With Short-Term Mortality of Congestive Heart Failure: A Retrospective Cohort Study. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 753133	5.4	4
35	Risk prediction in medically treated chronic thromboembolic pulmonary hypertension. <i>BMC Pulmonary Medicine</i> , 2021 , 21, 128	3.5	1
34	Prevalence of -associated Pulmonary Hypertension in China: An Echocardiography-based Assessment. <i>Annals of the American Thoracic Society</i> , 2021 , 18, 2095-2098	4.7	2
33	Characteristics and long-term survival of patients with chronic thromboembolic pulmonary hypertension in China. <i>Respirology</i> , 2021 , 26, 196-203	3.6	8
32	Development and Validation of Nomogram to Predict Long-Term Prognosis of Critically Ill Patients with Acute Myocardial Infarction. <i>International Journal of General Medicine</i> , 2021 , 14, 4247-4257	2.3	2
31	Safety and efficacy of a platelet glycoprotein Ib inhibitor for patients with non-ST segment elevation myocardial infarction: A phase Ib/Ila study. <i>Pharmacotherapy</i> , 2021 , 41, 828-836	5.8	1
30	Serum Anion Gap Is Associated with All-Cause Mortality among Critically Ill Patients with Congestive Heart Failure. <i>Disease Markers</i> , 2020 , 2020, 8833637	3.2	3
29	NLRC3 inhibits PDGF-induced PSMCs proliferation via PI3K-mTOR pathway. <i>Journal of Cellular Physiology</i> , 2020 , 235, 9557-9567	7	3
28	Combination of Dichloroacetate and Atorvastatin Regulates Excessive Proliferation and Oxidative Stress in Pulmonary Arterial Hypertension Development via p38 Signaling. <i>Oxidative Medicine and Cellular Longevity</i> , 2020 , 2020, 6973636	6.7	4
27	Rapid disease progress in a PVOD patient carrying a novel EIFAK mutation: a case report. <i>BMC Pulmonary Medicine</i> , 2020 , 20, 186	3.5	2
26	Two-year follow-up of a randomized multicenter study comparing a drug-coated balloon with a drug-eluting stent in native small coronary vessels: The RESTORE Small Vessel Disease China trial. <i>Catheterization and Cardiovascular Interventions</i> , 2020 , 95 Suppl 1, 587-597	2.7	12
25	Three-year follow up of biodegradable polymer cobalt-chromium sirolimus-eluting stent (EXCROSSAL) in treating de novo coronary artery disease: Pooled analysis of CREDIT II and CREDIT III trials. <i>Catheterization and Cardiovascular Interventions</i> , 2020 , 95 Suppl 1, 565-571	2.7	2
24	NLRC3 Delays the Progression of AD in APP/PS1 Mice via Inhibiting PI3K Activation. <i>Oxidative Medicine and Cellular Longevity</i> , 2020 , 2020, 5328031	6.7	4

23	Nucleolin promotes Ang II-induced phenotypic transformation of vascular smooth muscle cells by regulating EGF and PDGF-BB. <i>Journal of Cellular and Molecular Medicine</i> , 2020 , 24, 1917-1933	5.6	5
22	Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension. A Double-Blind Placebo-controlled Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020 , 201, 707-717	10.2	40
21	The Association between Trimethylamine N-Oxide and Its Predecessors Choline, L-Carnitine, and Betaine with Coronary Artery Disease and Artery Stenosis. <i>Cardiology Research and Practice</i> , 2020 , 2020, 5854919	1.9	4
20	Effect of ambrisentan on echocardiographic and Doppler measures from patients in China with pulmonary arterial hypertension. <i>Expert Review of Cardiovascular Therapy</i> , 2020 , 18, 643-649	2.5	0
19	Identification of Biomarkers Related to Systemic Sclerosis With or Without Pulmonary Hypertension Using Co-expression Analysis. <i>Journal of Computational Biology</i> , 2020 , 27, 1519-1531	1.7	3
18	YINGLONG: A Multicenter, Prospective, Non-Interventional Study Evaluating the Safety and Tolerability of Ticagrelor in Chinese Patients with Acute Coronary Syndrome. <i>Advances in Therapy</i> , 2019 , 36, 1595-1605	4.1	0
17	Galectin-3 Mediates Endothelial-to-Mesenchymal Transition in Pulmonary Arterial Hypertension 2019 , 10, 731-745		9
16	Nucleolin promotes AngII-induced phenotypic transformation of vascular smooth muscle cells via interaction with tropoelastin mRNA. <i>International Journal of Molecular Medicine</i> , 2019 , 43, 1597-1610	4.4	1
15	NLRC3 inhibits MCT-induced pulmonary hypertension in rats via attenuating PI3K activation. <i>Journal of Cellular Physiology</i> , 2019 , 234, 15963	7	11
14	The association of metabolic syndrome components and chronic kidney disease in patients with hypertension. <i>Lipids in Health and Disease</i> , 2019 , 18, 229	4.4	17
13	microRNA-423-3p exosomes derived from cardiac fibroblasts mediates the cardioprotective effects of ischaemic post-conditioning. <i>Cardiovascular Research</i> , 2019 , 115, 1189-1204	9.9	45
12	The effectiveness and safety of the RESTORE drug-eluting balloon versus a drug-eluting stent for small coronary vessel disease: study protocol for a multi-center, randomized, controlled trial. <i>Journal of Geriatric Cardiology</i> , 2018 , 15, 469-475	1.7	2
11	Drug-Coated Balloon Versus Drug-Eluting Stent for Small-Vessel Disease: The RESTORE SVD China Randomized Trial. <i>JACC: Cardiovascular Interventions</i> , 2018 , 11, 2381-2392	5	45
10	NLRC3: A Novel Noninvasive Biomarker for Pulmonary Hypertension Diagnosis 2018 , 9, 843-851		2
9	Critical role of vascular peroxidase 1 in regulating endothelial nitric oxide synthase. <i>Redox Biology</i> , 2017 , 12, 226-232	11.3	21
8	Galectin-3 mediates the pulmonary arterial hypertension-induced right ventricular remodeling through interacting with NADPH oxidase 4. <i>Journal of the American Society of Hypertension</i> , 2017 , 11, 275-289.e2		46
7	Impact of interaction between CYP1A1 genetic polymorphisms and smoking on coronary artery disease in the Han of China. <i>Clinical and Experimental Hypertension</i> , 2017 , 39, 339-343	2.2	8
6	Association of Serum Prealbumin with Angiographic Severity in Patients with Acute Coronary Syndrome. <i>Medical Science Monitor</i> , 2017 , 23, 4041-4049	3.2	13

- 5 Galectin-3 mediates pulmonary vascular remodeling in hypoxia-induced pulmonary arterial hypertension. *Journal of the American Society of Hypertension*, **2017**, 11, 673-683.e3 21
- 4 Involvement of vascular peroxidase 1 in angiotensin II-induced hypertrophy of H9c2 cells. *Journal of the American Society of Hypertension*, **2017**, 11, 519-529.e1 11
- 3 Vascular peroxidase 1 up regulation by angiotensin II attenuates nitric oxide production through increasing asymmetrical dimethylarginine in HUVECs. *Journal of the American Society of Hypertension*, **2016**, 10, 741-751.e3 10
- 2 The role of vascular peroxidase 1 in ox-LDL-induced vascular smooth muscle cell calcification. *Atherosclerosis*, **2015**, 243, 357-63 3.1 31
- 1 HIV protease inhibitors in pulmonary hypertension: rationale and design of a pilot trial in idiopathic pulmonary arterial hypertension. *Pulmonary Circulation*, **2015**, 5, 538-46 2.7 2